| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -40,132 | -26,874 |
| Stock-based compensation | 2,783 | 1,736 |
| Operating lease right-of-use asset | 803 | 530 |
| Depreciation | 269 | 181 |
| Amortization of premium (accretion of discount) on marketable debt securities | -928 | -532 |
| Prepaid expenses and other current assets | 1,111 | 1,012 |
| Other assets | -262 | -204 |
| Accounts payable | 689 | 1,484 |
| Accrued expenses and other current liabilities | -1,223 | -2,145 |
| Operating lease liabilities | -827 | -535 |
| Net cash provided by (used in) operating activities | -39,415 | -26,963 |
| Purchase of marketable debt securities | 141,923 | 117,511 |
| Proceeds from maturity and redemption of marketable debt securities | 29,410 | 11,500 |
| Purchase of property and equipment | 70 | 66 |
| Net cash provided by (used in) investing activities | -112,583 | -106,077 |
| Proceeds from exercise of underwriters option in december 2024 public offering, net of offering costs of 214 | 2,528 | 2,528 |
| Offering costs paid in connection with the december 2024 public offering | 614 | 614 |
| Proceeds from private placement, net of offering costs of 3,034 | - | 0 |
| Proceeds from exercise of pre-funded warrants | 1 | 1 |
| Taxes paid related to net share settlement of restricted stock units | 185 | 185 |
| Proceeds from exercise of stock options | 21 | 8 |
| Net cash provided by (used in) financing activities | 1,751 | 1,738 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | -150,247 | -131,302 |
| Cash and cash equivalents at beginning of period | 163,543 | - |
| Cash and cash equivalents at end of period | 13,296 | - |
Protara Therapeutics, Inc. (TARA)
Protara Therapeutics, Inc. (TARA)